Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. News
  7. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : German labs supplier Merck raises forecast on strong first quarter

05/04/2021 | 03:13pm EDT
FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt

FRANKFURT (Reuters) - German biotech labs supplier Merck raised its 2021 earnings forecast on strong first-quarter results, as efforts by the pharma industry to ready treatments and vaccines against the coronavirus bolsters demand for its products.

The company, which also makes pharmaceuticals and specialty chemicals, said that it now expects 2021 adjusted earnings before interest, tax, depreciation and amortization of 5.4-5.8 billion euros, and revenues of 18.5-19.5 billion.

It had earlier guided for core earnings to grow organically by a high single-digit to low teens percentage figure and strong organic revenue growth.

In the first quarter, EBITDA reached 1.51 billion euros, while revenues came in at 4.63 billion.

Merck is expected to publish first-quarter 2021 figures as scheduled on May 12.

(Reporting by Arno Schuetze; Editing by Chizu Nomiyama)


© Reuters 2021
All news about MERCK KGAA
06:03aMERCK  : Joins Research Project to Optimize Energy Use in Darmstadt, Germany
MT
05/07MERCK KGAA  : quaterly earnings release
05/07MERCK  : ALJ Bullock Grants-in-Part Motion For Summary Determination Of Violatio..
AQ
05/06MERCK KGAA  : Buy rating from Deutsche Bank
MD
05/05GLOBAL MARKETS LIVE : Lyft, Activision, General Electric...
05/05MERCK KGAA  : DZ Bank maintains a Buy rating
MD
05/05MERCK KGAA  : Warburg Research reaffirms its Neutral rating
MD
05/05MERCK KGAA  : UBS gives a Neutral rating
MD
05/05MERCK KGAA  : Sell rating from Goldman Sachs
MD
05/05MERCK KGAA  : JP Morgan keeps its Buy rating
MD
More news
Financials
Sales 2021 18 596 M 22 602 M 22 602 M
Net income 2021 2 349 M 2 855 M 2 855 M
Net Debt 2021 9 319 M 11 327 M 11 327 M
P/E ratio 2021 25,8x
Yield 2021 1,04%
Capitalization 61 586 M 74 941 M 74 854 M
EV / Sales 2021 3,81x
EV / Sales 2022 3,50x
Nbr of Employees 58 127
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 146,51 €
Last Close Price 141,65 €
Spread / Highest target 23,5%
Spread / Average Target 3,43%
Spread / Lowest Target -22,3%
EPS Revisions
Managers and Directors
NameTitle
Belén Garijo López Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Nilesh Kumar Senior Investment Director
Christian Raabe Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA0.93%74 895
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD23.59%31 537
KYOWA KIRIN CO., LTD.19.05%16 673
SK BIOPHARMACEUTICALS CO., LTD.-36.09%7 710
BETTA PHARMACEUTICALS CO., LTD.-7.96%6 131
YUHAN CORPORATION-15.98%3 797